Skin B cells in the progression from cutaneous lupus to systemic lupus

Conditions: Cutaneous lupus
skin lupus
10003816
10014982

Registration Number: NL-OMON56119

Lead Sponsor: eids Universitair Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: 50

Inclusion Criteria

1. Age >= 18 years.
2. Diagnosis of CLE is made by dermatologist based on clinical features and
histopathological examination.
3. In case of a SLE, this diagnosis is made by a rheumatologist based on 2019
ACR/EULAR classification criteria for SLE.
4. Patients who have read, understood, and signed an informed consent document
related to this specific study.

Exclusion Criteria

- Patients with any other dermatological of systemic disorder which would
interfere with the results, at the discretion of the investigator.
- Patients using topical corticosteroids and topical calcineurin inhibitors at
biopsy site within one week prior to enrolment.
- Patients who are or have been treated with specific B cell
depleting/modifying therapies (Rituximab, Belimumab, Cyclophosphamide)in 12
months prior to inclusion.

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Objective 1: Characterization of autoreactive B cells in CLE and SLE<br /><br>• Frequency and phenotype of autoreactive B cells in skin and circulation<br /><br>• Specificities of antibodies from cutaneous B cell supernatant in ELISA<br /><br><br /><br>Objective 2: Determine the mechanisms for B cell tolerance breakthrough and<br /><br>plasma cell differentiation in the skin of CLE and SLE patients<br /><br>• Transcriptome of B cells in skin (scRNAseq)<br /><br>• B cell receptor repertoire of cutaneous B cells<br /><br>• Immune cell landscape of B cells in skin (imaging mass cytometry).</p><br>

Secondary Outcome Measures